Loading lessons…
Peptide learning paths
Learn peptides step by step
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
238lessons
8paths
0day streak
0%explored
Start your first lesson
Choose a learning path below or search the library. Progress saves in your browser.
Learning paths
Pick a track — progress rings update as you complete lessons.
21 lessons
9mProtocolsIntermediate
MariTide Dosing Guide: Once-Monthly 140–420 mg Phase 2 Map
MariTide is the once-monthly obesity candidate people keep comparing to weekly GLP-1s. Here's the Phase 2 dosing map — 140 / 280 / 420 mg and the escalation arms that mattered for tolerability.
8mSafetyIntermediate
MariTide Beginner's Guide: What Maridebart Cafraglutide Is
MariTide is Amgen's once-monthly obesity candidate. This beginner guide covers the mechanism framing, Phase 2 headlines, and what serious trackers should log.
8mProtocolsIntermediate
MariTide vs Weekly GLP-1s: Monthly Conjugate vs Weekly Agonists
Weekly vs monthly is the real MariTide comparison. Here's how Amgen's conjugate stacks up conceptually against weekly dual/triple agonists — without fake head-to-heads.
7mSafetyIntermediate
MariTide Side Effects: GI Tolerability and Monthly Titration
Monthly conjugates can pack a bigger post-dose GI window. Here's how to think about MariTide tolerability using Phase 2 lessons — without fear content.
8mProtocolsIntermediate
CT-388 Dosing Guide: Weekly Dual GLP-1/GIP Up to 24 mg
CT-388 is Roche's weekly tirzepatide-class dual agonist with Phase 2 doses up to 24 mg. Here's the dosing vocabulary and the weight-loss signal searchers want.
7mResearchAdvanced
Petrelintide Beginner's Guide: Roche/Zealand's Weekly Amylin Analog
Petrelintide is the amylin analog drawing attention for tolerability. This beginner guide covers what it is, what ZUPREME-1 showed, and what to watch next.
8mProtocolsIntermediate
Petrelintide Dosing Guide: Once-Weekly Amylin Analog Titration
Petrelintide is the Roche/Zealand once-weekly amylin analog drawing GLP-1-level attention for tolerability. Here's the Phase 2 dosing pattern, results, and what to track.
8mResearchAdvanced
Eloralintide vs Petrelintide: Lilly vs Roche Amylin Agonists
Two weekly amylin programs, two sponsors, two data shapes. Here's a clear eloralintide vs petrelintide comparison for people following the next obesity wave.
9mPeptidesIntermediate
Eloralintide Beginner's Guide: What LY3841136 Is and Why Amylin Matters
Eloralintide is Lilly's once-weekly selective amylin receptor agonist. If you follow GLP-1s, CagriSema, or retatrutide, this is the next pathway to understand — satiety biology, trial doses, and what the early data actually show.
8mProtocolsIntermediate
Eloralintide Dosing Guide: Phase 2 Doses, Titration, and Weekly Protocol
Searching for eloralintide dosage? Here is the clean map of Phase 2 once-weekly doses, titration arms, and weight-loss results — framed as clinical education, not a DIY protocol.
8mProtocolsIntermediate
Eloralintide + GLP-1 / Tirzepatide: The Amylin Add-On Stack Explained
Amylin + incretin is the stacking thesis behind CagriSema — and now eloralintide. Here's the clinical logic for combining pathways, without turning investigational drugs into DIY stacks.
7mSafetyIntermediate
Eloralintide Side Effects: What Phase 2 Tolerability Data Suggests
Amylin agonists can feel GLP-1-like in the gut. Here's how to think about eloralintide tolerability, escalation, and symptom tracking without turning trial data into fear content.
8mResearchAdvanced
Eloralintide Weight Loss Results: Phase 2 Data and What to Watch in Phase 3
Phase 2 put eloralintide on the board with roughly 9–20% mean weight loss at 48 weeks. Here's the results breakdown — and the troubleshooting mindset for plateaus on any amylin or GLP-1 protocol.
8mProtocolsIntermediate
Survodutide Dosing Guide: Phase 2–3 Weekly Doses for Obesity
Survodutide is Boehringer's glucagon/GLP-1 dual agonist. Here's the dosing map from dose-finding through Phase 3 — weekly mg ranges, escalation logic, and what the weight-loss data showed.
10mResearchAdvanced
Retatrutide's July 23 Phase 3 Readout Keeps Raising the Ceiling
Retatrutide just posted two more strong phase 3 wins. The new numbers matter, but the bigger story is how phase 1, phase 2, and phase 3 now line up into one very clear dose-response story.
8mResearchAdvanced
GHK-Cu Topical Gel Trial: What Wound Healing Data Could Show
GHK-Cu is moving beyond skin-care hype into a controlled wound-healing study. Here is how to read the Phase 2 trial without overclaiming the result.
8mResearchAdvanced
MOTS-c and Mitochondrial Metabolism: What the 2026 Human Trial Is Testing
MOTS-c is one of the most interesting mitochondrial peptides in 2026 because the question is finally shifting from mechanism to human outcomes.
7mResearchAdvanced
BPC-157 Hits a Milestone: The First Controlled Human Trial Is Now Recruiting
After 30+ years of animal research and 212 preclinical studies, BPC-157 has entered its first Phase 2 human trial. Here's what it will test, what it won't prove, and what to track.
8mResearchAdvanced
BPC-157 Human Hamstring Trial: Why This Study Matters
BPC-157 finally has a registered human sports-injury study. The signal is important, but it is not proof yet. Here is how to read the trial without the hype.
9mPeptidesIntermediate
MOTS-c Enters Phase 2a Human Trial for Prediabetes: What the Research Shows
MOTS-c — a peptide synthesized inside your own mitochondria — is now in Phase 2a human trials for prediabetes. Early data suggests it improves insulin sensitivity and metabolic flexibility without the side effects of pharmaceutical interventions.
9mPeptidesIntermediate
GHK-Cu: The Copper Peptide Accelerating Wound Healing and Skin Regeneration
A 2026 Phase 2 clinical trial confirms GHK-Cu achieves 25% faster wound closure and tissue regeneration versus control. Discover how this naturally occurring copper peptide triggers stem cell activity, collagen synthesis, and anti-inflammatory cascades.
Also available at /blog for legacy links.